Sperm-peritoneal fluid incubation test: influence of a GnRH agonist treatment.
Objectives of our work were to determine whether the presence of endometriosis, stage and the activity of the disease influence the sperm-peritoneal fluid (PF) incubation test and, possibly, whether a GnRH agonist (GnRHa) treatment in these patients can reduce the PF toxicity toward sperms. Preovulatory PFs from 18 patients with endometriosis (11 stage I-II rAFS and/stage III-IV; 10 with active lesions and 8 with inactive disease), and from 15 women with unexplained infertility were collected and frozen at the time of diagnostic laparoscopy. The ten patients with active endometriosis were treated by 3 months ovarian desensitization by a GnRH a (Decapeptyl 3.75 mg, Ipsen, Milan Italy) followed by a controlled ovarian hyperstimulation with a purified FSH (Metrodin, Serono, Rome, Italy) and HCG 10.000 UI (Profasi, Serono) when appropriate. In these patients, immediately before performing intrauterine and/or intraperitoneal insemination, a small aliquot of PF was collected transvaginally checking the absence of oocytes. Five hundreds suspension for one hour. PFs inducing a decrease in sperm motility greater than 20% were defined "toxic". The prevalence of toxic PF was not statistically greater in endometriosis (8/18) than in unexplained infertility (3/15) and was not dependent upon the stage of the disease, while it was significantly (rho = 0.01) more frequent in patients with active endometriosis (7/10) than other women (4/23). After a three months GnRHa treatment of these patients the rate of toxic PFs was significantly (p = 0.02) decreased (1 out of 10 treated cases).(ABSTRACT TRUNCATED AT 250 WORDS)
Zullo
F
F
Dept of Gynecological and Pediatric Sciences, Catanzaro, School of Medicine, Italy.
Corea
D
D
Torano
P
P
Placco
C
C
Tropea
G
G
Mastrantonio
P
P
D001202:Ascitic Fluid; D004715:Endometriosis / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000503:physiopathology; D008297:Male; D010062:Ovulation Induction; D015995:Prevalence; D012099:Reproductive Techniques; D012720:Severity of Illness Index; D013081:Sperm Motility / Q000187:drug effects / Q000502:physiology; D013094:Spermatozoa / Q000187:drug effects* / Q000502:physiology*; D017329:Triptorelin Pamoate / Q000494:pharmacology*
D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone